AbbVie has finally claimed FDA approval for its advanced Parkinson's disease therapy Vyalev, 18 months after the US regulator turned it down with a request for more data. Now, Vyalev (foscarbidopa and ...
We independently review everything we recommend. We may get paid to link out to retailer sites, and when you buy through our links, we may earn a commission. Learn more› By Thom Dunn Thom Dunn is a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback